Ignite Creation Date:
2025-12-25 @ 3:27 AM
Ignite Modification Date:
2026-06-25 @ 12:28 AM
Study NCT ID:
NCT07296705
Status:
RECRUITING
Last Update Posted:
2025-12-22
First Post:
2025-09-26
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Neoadjuvant Zanidatamab + Tislelizumab + Chemotherapy for Selective Bladder Preservation in HER2-Positive MIBC
Sponsor:
Fujian Medical University Union Hospital
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Muscle Invasive Bladder Cancer (MIBC) | View |
Keywords: